Crinetics Pharmaceuticals (CRNX) Interest Expenses (2017)
Crinetics Pharmaceuticals' quarterly Interest Expenses came in at $1000.0 in Q4 2017, down 50.0% quarter-over-quarter from $2000.0 in Q3 2017.
Crinetics Pharmaceuticals has reported Interest Expenses for 1 years, with the latest figure at $1000.0 in Q4 2017.
- For the quarter ending Q4 2017, Interest Expenses changed N/A year-over-year to $1000.0; the trailing twelve-month figure through Sep 2018 stood at $1000.0 (changed N/A YoY), and the FY2017 full-year result was $8000.0, down 27.27% from the prior year.
- Interest Expenses for Q4 2017 stood at $1000.0, down from $2000.0 in the prior quarter.
- The five-year high for Interest Expenses was $3000.0 in Q2 2017, with the low at $1000.0 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 1,000.00 |
| Dec 31, 2017 | 1,000.00 |
| Sep 30, 2017 | 2,000.00 |
| Sep 30, 2017 | 2,000.00 |
| Jun 30, 2017 | 3,000.00 |
| Jun 30, 2017 | 3,000.00 |